Germany · Delayed Price · Currency is EUR Pulse Biosciences Statistics
Total Valuation
FRA:6L8 has a market cap or net worth of EUR 772.39 million. The enterprise value is 697.28 million.
| Market Cap | 772.39M |
| Enterprise Value | 697.28M |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 67.77M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +15.44% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 73.14% |
| Owned by Institutions (%) | 8.72% |
| Float | 17.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10,537.68 |
| PB Ratio | 9.78 |
| P/TBV Ratio | 10.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.95 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -16.77 |
Financial Position
The company has a current ratio of 10.02, with a Debt / Equity ratio of 0.09.
| Current Ratio | 10.02 |
| Quick Ratio | 9.82 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.16 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -86.99% and return on invested capital (ROIC) is -52.47%.
| Return on Equity (ROE) | -86.99% |
| Return on Assets (ROA) | -48.90% |
| Return on Invested Capital (ROIC) | -52.47% |
| Return on Capital Employed (ROCE) | -79.69% |
| Revenue Per Employee | 977 |
| Profits Per Employee | -849,266 |
| Employee Count | 75 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.27% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -39.27% |
| 50-Day Moving Average | 14.01 |
| 200-Day Moving Average | 14.18 |
| Relative Strength Index (RSI) | 36.15 |
| Average Volume (20 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 12.96 |
Income Statement
In the last 12 months, FRA:6L8 had revenue of EUR 73,298 and -63.69 million in losses. Loss per share was -0.97.
| Revenue | 73,298 |
| Gross Profit | -164,494 |
| Operating Income | -67.29M |
| Pretax Income | -63.69M |
| Net Income | -63.69M |
| EBITDA | -66.35M |
| EBIT | -67.29M |
| Loss Per Share | -0.97 |
Balance Sheet
The company has 81.15 million in cash and 6.72 million in debt, giving a net cash position of 74.43 million.
| Cash & Cash Equivalents | 81.15M |
| Total Debt | 6.72M |
| Net Cash | 74.43M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 79.00M |
| Book Value Per Share | 1.17 |
| Working Capital | 74.54M |
Cash Flow
In the last 12 months, operating cash flow was -41.35 million and capital expenditures -224,155, giving a free cash flow of -41.57 million.
| Operating Cash Flow | -41.35M |
| Capital Expenditures | -224,155 |
| Free Cash Flow | -41.57M |
| FCF Per Share | n/a |
Margins
| Gross Margin | -224.42% |
| Operating Margin | -91,798.59% |
| Pretax Margin | -86,898.60% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:6L8 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.44% |
| Shareholder Yield | -15.44% |
| Earnings Yield | -8.25% |
| FCF Yield | -5.38% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:6L8 has an Altman Z-Score of 34 and a Piotroski F-Score of 1.
| Altman Z-Score | 34 |
| Piotroski F-Score | 1 |